Sign up to save your podcasts
Or
Share π Block. Beat. Benefit. The Hidden Strength of Ξ²-Blockers Post-MI
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
π Block. Beat. Benefit. The Hidden Strength of Ξ²-Blockers Post-MI
π¨ New Meta-Analysis Alert! ππ«
Can Ξ²-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40β49%)?
π An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with Ξ²-blockers vs. control (HR 0.75; p=0.031) β even in the absence of clinical heart failure.
π Consistent across trials and countries. Most benefit seen in patients
π This could shift guidelines for a large overlooked population.
π Read more in The Lancet (Aug 30, 2025)
#Cardiology #BetaBlockers #MyocardialInfarction #LVEF #EvidenceBasedMedicine #MetaAnalysis #HeartHealth ππ
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
π¨ New Meta-Analysis Alert! ππ«
Can Ξ²-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40β49%)?
π An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with Ξ²-blockers vs. control (HR 0.75; p=0.031) β even in the absence of clinical heart failure.
π Consistent across trials and countries. Most benefit seen in patients
π This could shift guidelines for a large overlooked population.
π Read more in The Lancet (Aug 30, 2025)
#Cardiology #BetaBlockers #MyocardialInfarction #LVEF #EvidenceBasedMedicine #MetaAnalysis #HeartHealth ππ
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
906 Listeners
The Curbsiders Internal Medicine Podcast
3,383 Listeners
The Mel Robbins Podcast
20,555 Listeners